Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

VSTM
Verastem, Inc.
stock NASDAQ

At Close
May 7, 2026 3:59:58 PM EDT
5.66USD-5.740%(-0.35)2,784,405
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 7, 2026 9:25:30 AM EDT
5.99USD-0.333%(-0.02)1,607
After-hours
May 7, 2026 4:58:30 PM EDT
5.40USD-4.701%(-0.27)60,025
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
07:10AM EST  Verastem Oncology Outlines 2022 Priorities And Upcoming Catalysts   Benzinga
07:00AM EST  Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers   Business Wire
Jan 7, 2022
07:00AM EST  Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Jan 4, 2022
04:05PM EST  Verastem Oncology to Participate in Upcoming Investor Conferences   Business Wire
Dec 23, 2021
07:29AM EST  The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review   Benzinga
Nov 22, 2021
07:41AM EST  Mirati, Verastem Partner To Evaluate Adagrasib In Combination With VS-6766 In KRASG12C-Mutant Non-Small Cell Lung Cancer   RTTNews
07:35AM EST  Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer   Benzinga
07:31AM EST  Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in   PR Newswire
07:30AM EST  Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer   Business Wire
Nov 11, 2021
07:00AM EST  Verastem Oncology to Present at the Jefferies London Healthcare Conference   Business Wire
Nov 5, 2021
09:24AM EDT  Verastem Oncology Q3 EPS $(0.07) Down From $0.11 YoY   Benzinga
Nov 4, 2021
04:05PM EDT  Verastem Oncology Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress   Business Wire
Oct 26, 2021
07:00AM EDT  Verastem Oncology Appoints Michelle Robertson to Board of Directors   Business Wire
Sep 24, 2021
04:05PM EDT  Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Sep 22, 2021
07:16AM EDT  Verastem Oncology Appoints Louis J. Denis, M.D., As Chief Medical Officer   Benzinga
07:08AM EDT  Verastem Oncology Appoints Louis Denis As Chief Medical Officer   RTTNews
07:00AM EDT  Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer   Business Wire
Sep 20, 2021
12:07PM EDT  Why Verastem Shares Are Trading Higher Today   Benzinga
07:16AM EDT  Verastem Oncology,Amgen Partner To Evaluate VS-6766 In With LUMAKRASTM In Patients With KRAS G12C-Mutant NSCLC   RTTNews
07:02AM EDT  Verastem Oncology And Amgen Partner To Evaluate VS-6766 In Combination With LUMAKRASTM In Patients With KRAS G12C-Mutant Non-Small Cell Lung Cancer   Benzinga
07:00AM EDT  Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer   Business Wire
06:42AM EDT  Verastem Oncology On Sunday Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data Of VS-6766 With Defactinib In Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates And Progression-Free Survival Presented at ESMO 2021   Benzinga
06:05AM EDT  The following are some of the stocks making big moves in Monday's pre-market trading (as of 5.35 A.M. EDT).   RTTNews
Sep 19, 2021
12:05PM EDT  Verastem Oncology Presents Updated Phase 1/2 FRAME Data Of VS-6766 With Defactinib In Serous Ovarian Cancer At ESMO   RTTNews
11:30AM EDT  Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021   Business Wire
09:46AM EDT  The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions and Conference Presentations In The Spotlight   Benzinga
Sep 7, 2021
07:00AM EDT  Verastem Oncology to Present at Upcoming Investor Conferences   Business Wire
Aug 2, 2021
04:24PM EDT  Verastem Oncology Q2 EPS $(0.08) Up From $(0.12) YoY, Sales $500.00K Down From $4.31M YoY   Benzinga
04:05PM EDT  Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress   Business Wire
Jul 27, 2021
11:13AM EDT  Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021   Benzinga
Jul 20, 2021
06:08AM EDT  HC Wainwright & Co. Maintains Buy on Verastem, Raises Price Target to $5   Benzinga
Jul 19, 2021
04:01PM EDT  Axogen, Inc. Appoints John H. Johnson to Board of Directors   GlobeNewswire Inc
07:04AM EDT  Verastem Says it Expects Current Cash to Last Until 2024   Benzinga
07:00AM EDT  Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt   Business Wire
Jul 6, 2021
07:06AM EDT  Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   RTTNews
Jul 1, 2021
10:11AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2021   Benzinga
07:29AM EDT  Alliance Global Partners Initiates Coverage On Verastem with Buy Rating, Announces Price Target of $6   Benzinga
Jun 24, 2021
07:11AM EDT  Verastem Oncology Appoints Paul Bunn And Lesley Solomon To Board   RTTNews
07:00AM EDT  Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors   Business Wire
Jun 23, 2021
04:44AM EDT  44 Biggest Movers From Yesterday   Benzinga
Jun 15, 2021
02:33PM EDT  Verastem Shares Tick Higher Over Last Few Mins. Following ~618K Share Block Trade   Benzinga
08:07AM EDT  The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda   Benzinga
Jun 9, 2021
09:14AM EDT  The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US   Benzinga
Jun 8, 2021
09:17AM EDT  The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex   Benzinga
May 25, 2021
07:53AM EDT  The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal   Benzinga
07:00AM EDT  Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference   Business Wire
May 24, 2021
12:06PM EDT  BTIG Upgrades Verastem to Buy, Announces $8 Price Target   Benzinga
12:03PM EDT  Verastem's VS-6766/Defactinib Combo Gets Breakthrough Therapy Tag For Ovarian Cancer; BTIG Upgrades Stock   Benzinga
07:09AM EDT  Verastem Gets Breakthrough Therapy Designation For VS-6766 With Defactinib In Recurrent Low-Grade Serous Ovarian Cancer   RTTNews
07:04AM EDT  Verastem Oncology Receives FDA Breakthrough Therapy Designation For VS-6766 With Defactinib In Recurrent Low-Grade Serous Ovarian Cancer   Benzinga
May 21, 2021
07:26AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying   Benzinga
May 20, 2021
08:27AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks   Benzinga
May 13, 2021
06:25AM EDT  HC Wainwright & Co. Maintains Buy on Verastem, Raises Price Target to $4   Benzinga
May 11, 2021
04:28PM EDT  Verastem Oncology Q1 Adj. EPS $(0.07) Up From $(0.20) YoY, Sales $1.00M Down From $5.06M YoY   Benzinga
04:05PM EDT  Verastem Oncology Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress   Business Wire
Apr 29, 2021
08:15AM EDT  The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx   Benzinga
Apr 28, 2021
07:26AM EDT  The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping   Benzinga
Mar 26, 2021
07:20AM EDT  CHMP Says On Mar. 25 Adopted Positive Opinion Recommending Granting Marketing Authorization For Copiktra To Verastem   Benzinga
Mar 19, 2021
10:43AM EDT  Verastem shares were trading lower after the company reported Q4 sales results down from last year.   Benzinga
Mar 18, 2021
04:10PM EDT  Verastem Oncology Q4 EPS $(0.09) Up From $(0.40) YoY, Sales $500.00K Down From $3.62M YoY   Benzinga
04:05PM EDT  Verastem Oncology Reports Fourth Quarter and Full Year 2020 Financial Results, Clinical Updates and Guidance for Key Milestones in 2021 and 1H 2022   Business Wire
Mar 2, 2021
07:00AM EST  Verastem Oncology to Participate in the H.C. Wainwright Global Life Sciences Conference   Business Wire
Jan 20, 2021
08:00AM EST  Frank Neumann, M.D., Ph.D., to Depart Verastem Oncology   Business Wire
Jan 7, 2021
04:05PM EST  Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Jan 6, 2021
09:15AM EST  Verastem Appoints Frank Neumann As Chief Medical Officer   RTTNews
09:13AM EST  Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer   Business Wire
Jan 5, 2021
07:00AM EST  Verastem Oncology to Present at the H.C. Wainwright BioConnect 2021 Conference   Business Wire
Dec 15, 2020
07:10AM EST  Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer   Benzinga
Nov 30, 2020
07:11AM EST  Verastem Oncology Initiates Phase 2 Registration-Directed Trial Of VS-6766   RTTNews
07:03AM EST  Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer   Benzinga
Nov 27, 2020
10:17AM EST  Mid-Morning Market Update: Markets Open Higher; Disney Laying Off 32,000 Workers   Benzinga
Nov 9, 2020
04:26PM EST  Verastem Sees FY 2020 Operating Expenses Between $80M And $90M, Has Cash Runway Until At Least 2024   Benzinga
04:25PM EST  Verastem Oncology Q3 EPS $0.11 Up From $(0.35) YoY, Sales $78.60M Up From $9.03M YoY   Benzinga
04:05PM EST  Verastem Oncology Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress   Business Wire
Oct 29, 2020
07:30AM EDT  The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal   Benzinga
Oct 28, 2020
09:06PM EDT  Verastem Oncology New Data Supports Potential Of VS-6766 As Treatment For RAS Mutant Tumors   RTTNews
08:01PM EDT  Verastem Oncology Announces New Data Published in The Lancet Oncology Supports Potential of VS-6766 as Treatment for RAS Mutant Tumors   Business Wire
Oct 6, 2020
07:24AM EDT  Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   RTTNews
Sep 30, 2020
08:58AM EDT  Verastem Completes Sale Of COPIKTRA Or Duvelisib To Secura Bio   RTTNews
08:57AM EDT  Verastem Oncology Announces Closing Of COPIKTRA Sale To Secura Bio   Benzinga
08:54AM EDT  Verastem Oncology Announces Closing of COPIKTRA(r) (duvelisib) Sale to Secura Bio   Business Wire
Sep 16, 2020
07:07AM EDT  Verastem Oncology To Present Updated Phase 1/2 FRAME Study Data At Annual RAS-Targeted Drug Development Summit   RTTNews
07:07AM EDT  Verastem Oncology Announces Presentation Of Updated Phase 1/2 FRAME Study Data At 2nd Annual RAS-Targeted Drug Development Summit   Benzinga
Sep 14, 2020
07:00AM EDT  Verastem Oncology Announces Investor Conference Call to Discuss Updated Clinical Data in Low-Grade Serous Ovarian Cancer from Phase 1/2 FRAME Study   Business Wire
Sep 10, 2020
04:05PM EDT  Verastem Oncology to Present at Upcoming Investor Conferences   Business Wire
Aug 10, 2020
08:43AM EDT  Verastem Oncology Signs Definitive Agreement To Sell COPIKTRA Rights To Secura Bio   RTTNews
08:38AM EDT  Verastem Oncology Signs Definitive Agreement To Sell COPIKTRA Rights To Secura Bio To Focus On Development Of VS-6766 And Defactinib In KRAS Mutant Solid Tumors; Co. Will Receive $70M Upfront Payment, Total Deal Value $311M   Benzinga
08:33AM EDT  Verastem Oncology Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress   Business Wire
08:30AM EDT  Verastem Oncology Signs Definitive Agreement to Sell COPIKTRA(r) (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors   Business Wire
Jul 29, 2020
09:45AM EDT  VeraStem Shares Spike Higher; Traders Circulate Clinical Trial Titled 'Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19) (DAMPEN-CI)'   Benzinga
Jul 27, 2020
08:30AM EDT  Traders Circulate Clinicaltrials.gov Page Titled 'Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (DAMPEN-CI)' On Verastem/UPenn Study Sponsored By Emory   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC